Kala Azar in South Asia : current status and sustainable challenges /: current status and sustainable challenges. (2016)
- Record Type:
- Book
- Title:
- Kala Azar in South Asia : current status and sustainable challenges /: current status and sustainable challenges. (2016)
- Main Title:
- Kala Azar in South Asia : current status and sustainable challenges
- Further Information:
- Note: E. Noiri, T.K. Jha, editors.
- Editors:
- Noiri, E (Eisei)
MRCP, DTM, Jha, T. K - Contents:
- Preface; Contents; Contributors; Introduction Into Kala-Azar; 1 Pathology and Mechanism of Disease in Kala-Azar; Abstract; 1.1 Life Cycle of Leishmania Donovani; 1.1.1 The Amastigote Form Occurring in Humans; 1.1.2 The Promastigote Form Occurring in Sand Flies; 1.2 Pathogenesis and Pathology of Visceral Leishmaniasis; References; 2 Containing Post Kala-Azar Dermal Leishmaniasis (PKDL): Pre-requisite for Sustainable Elimination of Visceral Leishmaniasis (VL) from South Asia; Abstract; 2.1 Epidemiology; 2.2 Clinical Features; 2.3 Diagnosis; 2.4 Histopathology; 2.5 Treatment; 2.6 Pathogenesis. 2.7 Challenges for Sustainable Elimination of VL2.8 Methods and Strategies to Control PKDL; References; 3 Characteristics of Patients Visiting Suruya Kanta Kala-Azar Research Center in Mymensingh, Bangladesh; Data from a Patient Registry System; Abstract; 3.1 Introduction; 3.2 Methods; 3.3 Results; 3.4 Discussion; 3.5 Conclusion; References; Therapeutic Strategy to Deal with Emergence of Drug Resistance; 4 Epidemiology of Drug-Resistant Kala-Azar in India and Neighboring Countries; Abstract; 4.1 Introduction; 4.1.1 History of VL on the Indian Subcontinent; 4.1.2 Incidence of VL in Bangladesh. 4.1.3 Incidence of VL in Nepal4.1.4 Incidence of VL in Bhutan; 4.1.5 Incidence of VL in Thailand; 4.1.6 The Current Scenario of VL in South East Asia; 4.2 History of the Efficacy of Antileishmanial Drugs in South East Asia; 4.2.1 Sodium Stibogluconate (SSG) Resistance in Nepal; 4.2.2 Efficacy ofPreface; Contents; Contributors; Introduction Into Kala-Azar; 1 Pathology and Mechanism of Disease in Kala-Azar; Abstract; 1.1 Life Cycle of Leishmania Donovani; 1.1.1 The Amastigote Form Occurring in Humans; 1.1.2 The Promastigote Form Occurring in Sand Flies; 1.2 Pathogenesis and Pathology of Visceral Leishmaniasis; References; 2 Containing Post Kala-Azar Dermal Leishmaniasis (PKDL): Pre-requisite for Sustainable Elimination of Visceral Leishmaniasis (VL) from South Asia; Abstract; 2.1 Epidemiology; 2.2 Clinical Features; 2.3 Diagnosis; 2.4 Histopathology; 2.5 Treatment; 2.6 Pathogenesis. 2.7 Challenges for Sustainable Elimination of VL2.8 Methods and Strategies to Control PKDL; References; 3 Characteristics of Patients Visiting Suruya Kanta Kala-Azar Research Center in Mymensingh, Bangladesh; Data from a Patient Registry System; Abstract; 3.1 Introduction; 3.2 Methods; 3.3 Results; 3.4 Discussion; 3.5 Conclusion; References; Therapeutic Strategy to Deal with Emergence of Drug Resistance; 4 Epidemiology of Drug-Resistant Kala-Azar in India and Neighboring Countries; Abstract; 4.1 Introduction; 4.1.1 History of VL on the Indian Subcontinent; 4.1.2 Incidence of VL in Bangladesh. 4.1.3 Incidence of VL in Nepal4.1.4 Incidence of VL in Bhutan; 4.1.5 Incidence of VL in Thailand; 4.1.6 The Current Scenario of VL in South East Asia; 4.2 History of the Efficacy of Antileishmanial Drugs in South East Asia; 4.2.1 Sodium Stibogluconate (SSG) Resistance in Nepal; 4.2.2 Efficacy of Miltefosine in Nepal; 4.2.3 Efficacy of SSG in Bangladesh; 4.2.4 Changing Response to Different Antileishmanial Agents in India; 4.2.5 Changing Response to Diamidine Compounds; 4.2.6 Amphotericin B; 4.2.7 Liposomal Amphotericin B (AmBisome); 4.2.8 Paromomycin (Aminosidine). 4.2.9 Status of Oral Treatments for VL4.2.10 Miltefosine as a Treatment for VL; 4.2.11 Sitamaquin (WR 6026); 4.3 Combination Therapy for Indian VL; 4.3.1 Future Option of Combination Therapy (Immunotherapy); 4.4 Combination Therapy in VL Associated with HIV/AIDS; 4.5 Conclusion; Acknowledgments; References; 5 A Therapeutic Strategy for Treating Visceral Leishmaniasis in Regions with Drug Resistance; Abstract; 5.1 Introduction; 5.2 Antileishmanial Drugs; 5.2.1 Sodium Stibogluconate; 5.2.2 Amphotericin B; 5.2.3 Liposomal Drug Delivery System; 5.2.4 Paromomycin; 5.2.5 Miltefosine. 5.3 Regulations and Policy5.4 Prevention of Drug Resistance; 5.5 Rationale for Combination Chemotherapy; 5.6 Pharmacological Considerations for Combination Therapy; 5.7 Compliance with Treatment; 5.8 Response to Treatment in AIDS-Related Kala-Azar; 5.9 Investigational Drugs; 5.10 Conclusion; Acknowledgments; References; 6 Treatment of Post-kala-azar Dermal Leishmaniasis; Abstract; 6.1 Introduction; 6.2 Antimonials; 6.3 Amphotericin B; 6.4 Miltefosine; 6.5 Immunotherapy; 6.6 Resistance; 6.7 Combination Regimes; Acknowledgment; References; 7 Combination Therapy for Leishmaniases; Abstract. … (more)
- Edition:
- Second edition
- Publisher Details:
- Cham, Switzerland : Springer
- Publication Date:
- 2016
- Extent:
- 1 online resource
- Subjects:
- 616.9/364
Medicine
Kala-azar -- South Asia
HEALTH & FITNESS -- Diseases -- General
MEDICAL -- Clinical Medicine
MEDICAL -- Diseases
MEDICAL -- Evidence-Based Medicine
MEDICAL -- Internal Medicine
Kala-azar
Leishmaniasis, Visceral -- diagnosis
Biomedicine
Parasitology
Drug Resistance
Veterinary Medicine/Veterinary Science
Laboratory Medicine
Nephrology
Medical -- Pharmacology
Medical -- Veterinary Medicine -- General
Medical -- Laboratory Medicine
Medical -- Nephrology
Pharmacology
Veterinary medicine
Medical laboratory testing & techniques
Renal medicine & nephrology
Medical parasitology
Drug interactions
Veterinary medicine
Medical laboratories
Nephrology
Medical -- Parasitology
Medical parasitology
South Asia
Electronic books - Languages:
- English
- ISBNs:
- 9783319471013
3319471015 - Related ISBNs:
- 9783319436111
3319436112 - Notes:
- Note: Online resource; title from PDF title page (SpringerLink, viewed January 24, 2017).
- Access Rights:
- Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
- Access Usage:
- Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library HMNTS - ELD.DS.364390
- Ingest File:
- 01_338.xml